StockData
Novartis AG logo

Novartis AG

NVSNYSEPharmaceutical PreparationsFiscal year ends December 31Also trades as NVSEF
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 20-F on Feb 4, 2026Score 7/30
$160.79−0.31 (-0.19%)

Close on Oct 30, 2026Market cap $306.81BP/E 22.5Yield –

Novartis Fabhalta Global Growth in USD by Quarter

Fabhalta Global Growth in USD (% USD) (%)

Novartis Fabhalta Global Growth in USD: 59.0% in Q3 2026, down 180.0 pts from a year earlier.

Latest, Q3 2026
59.0%
Period ended Sep 30, 2026
Change on a year earlier
-180.0 pts
239.0% in Q3 2025
History
5 quarters
Since Q3 2025
Sources
5
Documents cited below

Where the Q3 2026 figure comes from

“|| Fabhalta 3 | 237 | 149 | 59 | 60”

Source: Novartis Form 6-K (0001114448-26-000014) ↗

Reported in Form 6-K & Form 20-F.

Quarterly history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedFabhalta Global Growth in USD (% USD) (%)Year on yearSource
Q3 2026Sep 30, 202659.0%-180.0 ptsNovartis Form 6-K (0001114448-26-000014) ↗
Q2 2026Jun 30, 202688.0%–Novartis Form 6-K (0001114448-26-000012) ↗
Q1 2026Mar 31, 2026109.0%–Novartis Form 6-K (0001114448-26-000010) ↗
Q4 2025Dec 31, 2025172.0%–Novartis Form 6-K (0001114448-26-000007) ↗
Q3 2025Sep 30, 2025239.0%–Novartis Form 6-K (0001114448-25-000003) ↗

Cite this data

StockData. (2026). Novartis Fabhalta Global Growth in USD (%), quarterly Q3 2025–Q3 2026 [Data set]. Compiled from Novartis SEC filings and investor materials. https://stockdatahq.com/stocks/nvs/kpis/brand-fabhalta-yoy-usd-pct

See every metric in the Novartis KPI table. Data updated Nov 2, 2026.